Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

In the first major deal at MIT’s ambitious overhaul of the old Volpe Center in Kendall Square, Cambridge drugmaker Biogen ...

The looming competition piles further pressure on Biogen, whose MS franchise is already ... Tecfidera's decline has made Tysabri Biogen's top-selling drug. Last year, Polpharma Biologics and ...

having started to feel the pinch with its current MS drugs like Tecfidera (dimethyl fumarate), Avonex (interferon beta-1a), and Tysabri (natalizumab). Tecfidera is being squeezed by cheaper ...

The company has an elaborate marketed product portfolio for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI ... and other drugs. The company is focusing on the four products it ...

However, there are still several questions surrounding the performance of obesity drugs ... product portfolio for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA.

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of "More Stamina," a gamified ...

Optum Rx has eliminated prior authorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...